查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1822372

2032 年麻疹、流行性腮腺炎和德国德国麻疹疫苗市场预测：按产品、疫苗类型、接种途径、年龄层、通路、最终用户和地区进行的全球分析

Measles, Mumps, Rubella Vaccines Market Forecasts to 2032 - Global Analysis By Product, Vaccine Type, Route of Administration, Age Group, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球麻疹、流行性腮腺炎和德国德国麻疹(MMR) 疫苗市场预计在 2025 年达到 57.3 亿美元，到 2032 年将达到 138.3 亿美元，预测期内的复合年增长率为 13.4%。

麻疹-流行性腮腺炎-德国德国麻疹(MMR) 疫苗是一种联合疫苗，可保护个人免受三种严重感染疾病：麻疹、流行性腮腺炎和德国德国麻疹。透过活化免疫反应，该疫苗可帮助人体抵抗这些病毒，并降低严重併发症的风险，包括脑肿胀、呼吸道感染疾病和出生缺陷。 MMR 疫苗主要在儿童时期接种，是公共卫生的基石，有助于实现群体免疫并防止疾病在世界各地传播。

根据世界卫生组织预测，2023年全球麻疹病例预计将比前一年激增79%以上，通报病例将超过30.6万例，而人们对疫苗的犹豫日益加剧，使情况更加恶化。

提高对疫苗可预防疾病的认识

各国政府和非政府组织正在利用数位平台和社区计画推广免疫接种计画。行动医疗应用程式与人工智慧提醒系统的整合，正在提高不同族群的疫苗接种依从性。透过实证讯息通讯来反驳错误讯息，正在增强家长对常规免疫接种的信心。在新兴国家，国际资助的学校免疫接种活动正在蓬勃发展。这种认知度的提升与儿童和成人族群中麻腮风（MMR）疫苗接种率的提高直接相关。

副作用和安全问题

媒体对罕见不利事件的夸大报道，导致某些地区出现疫苗接种犹豫。监管机构正在加强药物安全检测通讯协定，并强制要求透过数位医疗记录进行即时安全监控。製造商正在投资改进配方，以降低反应原性并提高耐受性。社群媒体平台上日益高涨的反疫苗情绪促使相关内容监管更加严格，并进行了有针对性的反疫苗宣传活动。这些与安全相关的担忧可能会减缓敏感人群的市场扩张。

加强疫苗接种需求不断增加

随着免疫力逐渐减弱，麻腮风（MMR）加强针在青少年和成年人中越来越受欢迎。卫生部门正在修订疫苗接种指南，将定期加强剂纳入其中，尤其是在流行地区。疫苗接种技术的进步，例如微针贴片和鼻内製剂，正在改善患者的体验和依从性。雇主和大学越来越强制要求接种疫苗，这带来了新的机构需求。数位健康平台正在实现个人化的疫苗追踪和后续注射的自动安排。这种不断变化的情况为製造商扩展产品系列和分销网络提供了机会。

来自替代疫苗的竞争

重组疫苗和基于mRNA的製剂的创新因其更高的功效和更快的生产週期而日益受到关注。一些地区正在采用个人化免疫策略，优先考虑针对特异性疾病的疫苗而非频谱疫苗。生物技术公司与公共卫生机构之间的策略伙伴关係正在加速下一代疫苗的开发。随着低温运输物流的改进，以前难以取得的疫苗正进入主流分销管道。如果没有持续的创新和差异化，传统的MMR疫苗可能会被这些新兴竞争对手抢走市场份额。

COVID-19的影响

封锁和医疗资源的重新分配推迟了小儿科咨询和疫苗接种。然而，这场危机凸显了免疫接种的重要性，并促使对疫苗基础设施进行新的投资。各国政府实施了补种宣传活动和数位追踪系统以迎头赶上。在行动受限的情况下，远端医疗平台和行动诊所已成为推广的重要工具。后疫情时代策略如今强调韧性供应链、分散式交付模式以及将麻腮风（MMR）疫苗纳入更广泛的疫情防范框架。

预测期内，联合疫苗市场预计将成为最大的市场

联合疫苗因其便利性和广泛的保护效力，预计将在预测期内占据最大的市场份额。这些剂型减少了所需的注射次数，并提高了儿童及其看护者的依从性。抗原稳定性和佐剂系统的技术改进提高了免疫抗原性。小儿科更倾向于联合疫苗，因为它可以提高临床工作流程的效率并减少预约次数。新型多抗原联合疫苗的监管核准正在扩大该领域的覆盖范围。随着医疗保健系统优先考虑整合免疫接种计划，联合疫苗有望保持主导地位。

预计预测期内小儿科诊所部门的复合年增长率最高。

预计小儿科诊所细分市场将在预测期内达到最高成长率。这些机构正越来越多地采用数位免疫记录和自动化排程系统。出生率的上升和基层医疗可近性的改善推动了小儿科就诊量的成长。诊所正在采用行动推广和社区参与模式，以涵盖服务匮乏的人群。基于人工智慧的诊断工具的整合正在增强早期发现和及时接种疫苗的能力。随着对预防性医疗保健的日益重视，小儿科诊所正成为免疫生态系统的核心节点。

比最大的地区

受医疗基础设施扩张和人口密度上升的推动，亚太地区预计将在预测期内占据最大市场份额。印度、中国和印尼等国家正在国际支持下扩大国家疫苗接种计画。行动医疗单位和数位化登记正在改善偏远地区的疫苗接种途径。地方政府正在投资本地生产，以减少对进口的依赖。官民合作关係正在加速低温运输发展和「最后一哩路」配送。

复合年增长率最高的地区：

在预测期内，受技术创新和积极主动的医疗政策推动，北美预计将呈现最高的复合年增长率。美国和加拿大正在将人工智慧和物联网融入其疫苗分发和监控系统。监管机构正在简化先进製剂和给药机制的核准。远端医疗平台正在将疫苗分发范围扩大到传统诊所之外。高昂的公共医疗成本和保险覆盖率正在推动疫苗的广泛应用。随着个人化疫苗接种策略的兴起，北美正成为全球疫苗推广的标竿。

免费客製化服务：

此报告的订阅者可以选择以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 最终用户分析
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球麻疹、流行性腮腺炎和德国麻疹(MMR) 疫苗市场（依产品）

  • MMR II
  • PRIORIX
  • Tresivac
  • MM-RvaxPro
  • 其他产品

6. 全球麻疹、流行性腮腺炎和德国麻疹(MMR) 疫苗市场（依疫苗类型）

  • 单一疫苗
  • 联合疫苗

7. 全球麻疹、流行性腮腺炎和德国麻疹(MMR) 疫苗市场（依接种途径）

  • 皮下注射
  • 肌肉注射

8. 全球麻疹、流行性腮腺炎和德国德国麻疹(MMR) 疫苗市场（依年龄层）

  • 婴儿（0-1岁）
  • 儿童（1至12岁）
  • 青年
  • 成人

9. 全球麻疹、流行性腮腺炎和德国麻疹(MMR) 疫苗市场依通路划分

  • 医院药房
  • 政府供应商
  • 零售药局
  • 非政府组织和国际援助项目

10. 全球麻疹、流行性腮腺炎和德国德国麻疹(MMR) 疫苗市场（依最终用户）

  • 医院
  • 公共卫生机构
  • 儿科诊所
  • 其他最终用户

11. 全球麻疹-流行性腮腺炎-德国麻疹（MMR）疫苗市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章：企业概况

  • Merck & Co., Inc.
  • Indian Immunologicals Ltd.
  • GlaxoSmithKline plc（GSK）
  • Meiji Seika Pharma Co., Ltd.
  • Sanofi
  • Panacea Biotec Ltd.
  • Serum Institute of India Pvt. Ltd.
  • LG Chem Ltd.
  • Bharat Biotech International Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Zydus Lifesciences Ltd.
  • Mitsubishi Tanabe Pharma Corporation
  • Bio-Med Pvt. Ltd.
  • IDT Biologika GmbH
  • Sinovac Biotech Ltd.
Product Code: SMRC31126

According to Stratistics MRC, the Global Measles, Mumps, Rubella (MMR) Vaccines Market is accounted for $5.73 billion in 2025 and is expected to reach $13.83 billion by 2032 growing at a CAGR of 13.4% during the forecast period. The Measles, Mumps, Rubella (MMR) vaccine is a combined immunization that shields individuals from three serious infectious diseases: measles, mumps, and rubella. By activating the immune response, it equips the body to resist these viruses, reducing risks of severe complications like brain swelling, respiratory infections, and birth defects. Administered primarily in childhood, MMR vaccination is a cornerstone of public health, helping achieve herd immunity and preventing widespread disease transmission worldwide.

According to WHO, measles cases surged by over 79% globally in 2023 compared to the previous year, with over 306,000 reported cases and a growing trend in vaccine hesitancy worsening the situation.

Market Dynamics:

Driver:

Increasing awareness about vaccine-preventable diseases

Governments and NGOs are leveraging digital platforms and community-based programs to promote immunization schedules. The integration of mobile health apps and AI-driven reminders is improving vaccine compliance across diverse populations. As misinformation is countered with evidence-based messaging, parental confidence in routine immunizations is rising. Emerging economies are witnessing a surge in school-based vaccination drives, supported by international funding. This growing consciousness is directly translating into higher uptake of MMR vaccines across both pediatric and adult cohorts.

Restraint:

Adverse effects and safety concerns

Media amplification of rare adverse events has led to vaccine hesitancy in certain regions. Regulatory bodies are tightening pharmacovigilance protocols and mandating real-time safety monitoring through digital health records. Manufacturers are investing in formulation improvements to reduce reactogenicity and enhance tolerability. The rise of anti-vaccine sentiment on social media platforms is prompting stricter content moderation and targeted counter-campaigns. These safety-related apprehensions may slow market expansion in sensitive demographics.

Opportunity:

Rising demand for booster immunizations

As immunity wanes over time, booster doses for MMR are gaining traction among adolescents and adults. Health authorities are revising immunization guidelines to include periodic boosters, especially in outbreak-prone zones. Technological advancements in vaccine delivery-such as microneedle patches and intranasal formulations-are improving patient experience and compliance. Employers and universities are increasingly mandating booster shots, creating new institutional demand. Digital health platforms are enabling personalized vaccine tracking and automated scheduling for follow-up doses. This evolving landscape presents a lucrative opportunity for manufacturers to expand product portfolios and distribution networks.

Threat:

Competition from alternative vaccines

Innovations in recombinant and mRNA-based formulations are drawing attention for their enhanced efficacy and faster production cycles. Some regions are adopting tailored immunization strategies that prioritize disease-specific vaccines over broad-spectrum ones. Strategic partnerships between biotech firms and public health agencies are accelerating the development of next-gen alternatives. As cold-chain logistics improve, previously inaccessible vaccines are entering mainstream distribution. Without continuous innovation and differentiation, traditional MMR products risk losing market share to these emerging contenders.

Covid-19 Impact

Lockdowns and healthcare resource reallocation delayed pediatric visits and vaccine administration. However, the crisis also underscored the importance of immunization, prompting renewed investment in vaccine infrastructure. Governments introduced catch-up campaigns and digital tracking systems to recover lost ground. Telehealth platforms and mobile clinics emerged as vital tools for vaccine outreach during restricted mobility. Post-Covid strategies now emphasize resilient supply chains, decentralized delivery models, and integration of MMR vaccines into broader pandemic preparedness frameworks.

The combination vaccines segment is expected to be the largest during the forecast period

The combination vaccines segment is expected to account for the largest market share during the forecast period, due to its convenience and broad-spectrum protection. These formulations reduce the number of injections required, improving compliance among children and caregivers. Technological enhancements in antigen stabilization and adjuvant systems are boosting immunogenicity. Pediatricians prefer combination vaccines for their efficiency in clinical workflows and reduced appointment frequency. Regulatory approvals for newer multi-antigen combinations are expanding the segment's reach. As healthcare systems prioritize integrated immunization schedules, combination vaccines are set to maintain their leadership position.

The pediatric clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the pediatric clinics segment is predicted to witness the highest growth rate. These facilities are increasingly equipped with digital immunization records and automated scheduling systems. Rising birth rates and improved access to primary care are driving footfall in pediatric settings. Clinics are adopting mobile outreach and community engagement models to reach underserved populations. Integration of AI-based diagnostic tools is enhancing early detection and timely vaccination. With growing emphasis on preventive care, pediatric clinics are becoming central nodes in the immunization ecosystem.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by expanding healthcare infrastructure and population density. Countries like India, China, and Indonesia are scaling up national immunization programs with international support. Mobile health units and digital registries are improving vaccine access in remote areas. Regional governments are investing in local manufacturing to reduce dependency on imports. Public-private partnerships are accelerating cold-chain development and last-mile delivery.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fuelled by technological innovation and proactive healthcare policies. The U.S. and Canada are integrating AI and IoT into vaccine distribution and monitoring systems. Regulatory agencies are streamlining approvals for advanced formulations and delivery mechanisms. Telemedicine platforms are expanding vaccine outreach beyond traditional clinics. High public health spending and insurance coverage are supporting widespread adoption. As personalized immunization strategies gain traction, North America continues to set benchmarks for global vaccine deployment.

Key players in the market

Some of the key players profiled in the Measles, Mumps, Rubella (MMR) Vaccines Market include Merck & Co., Inc., Indian Immunologicals Ltd., GlaxoSmithKline plc (GSK), Meiji Seika Pharma Co., Ltd., Sanofi, Panacea Biotec Ltd., Serum Institute of India Pvt. Ltd., LG Chem Ltd., Bharat Biotech International Ltd., Walvax Biotechnology Co., Ltd., Zydus Lifesciences Ltd., Mitsubishi Tanabe Pharma Corporation, Bio-Med Pvt. Ltd., IDT Biologika GmbH, and Sinovac Biotech Ltd.

Key Developments:

In July 2025, Merck and Verona Pharma plc announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Verona Pharma for $107 per American Depository Share (ADS), each of which represents eight Verona Pharma ordinary shares, for a total transaction value of approximately $10 billion.

In August 2024, Immunologicals Limited (IIL) has announced partnership with Central Institute of Brackishwater Aquaculture (CIBA), Chennai, an Indian Council of Agricultural Research (ICAR) Institute for the commercial development of a recombinant monovalent viral nervous necrosis vaccine for finfish developed by CIBA.

Products Covered:

  • M-M-R II
  • PRIORIX
  • Tresivac
  • M-M-RvaxPro
  • Other Product Types

Vaccine Types Covered:

  • Standalone Vaccines
  • Combination Vaccines

Route of Administrations Covered:

  • Subcutaneous Injections
  • Intramuscular Injections

Age Groups Covered:

  • Infants (0-1 year)
  • Children (1-12 years)
  • Adolescents
  • Adults

Distribution Channels Covered:

  • Hospital Pharmacies
  • Government Suppliers
  • Retail Pharmacies
  • NGO & International Aid Programs

End Users Covered:

  • Hospitals
  • Public Health Agencies
  • Pediatric Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Product

  • 5.1 Introduction
  • 5.2 M-M-R II
  • 5.3 PRIORIX
  • 5.4 Tresivac
  • 5.5 M-M-RvaxPro
  • 5.6 Other Product Types

6 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Vaccine Type

  • 6.1 Introduction
  • 6.2 Standalone Vaccines
  • 6.3 Combination Vaccines

7 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Subcutaneous Injections
  • 7.3 Intramuscular Injections

8 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Age Group

  • 8.1 Introduction
  • 8.2 Infants (0-1 year)
  • 8.3 Children (1-12 years)
  • 8.4 Adolescents
  • 8.5 Adults

9 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Government Suppliers
  • 9.4 Retail Pharmacies
  • 9.5 NGO & International Aid Programs

10 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Public Health Agencies
  • 10.4 Pediatric Clinics
  • 10.5 Other End Users

11 Global Measles, Mumps, Rubella (MMR) Vaccines Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Merck & Co., Inc.
  • 13.2 Indian Immunologicals Ltd.
  • 13.3 GlaxoSmithKline plc (GSK)
  • 13.4 Meiji Seika Pharma Co., Ltd.
  • 13.5 Sanofi
  • 13.6 Panacea Biotec Ltd.
  • 13.7 Serum Institute of India Pvt. Ltd.
  • 13.8 LG Chem Ltd.
  • 13.9 Bharat Biotech International Ltd.
  • 13.10 Walvax Biotechnology Co., Ltd.
  • 13.11 Zydus Lifesciences Ltd.
  • 13.12 Mitsubishi Tanabe Pharma Corporation
  • 13.13 Bio-Med Pvt. Ltd.
  • 13.14 IDT Biologika GmbH
  • 13.15 Sinovac Biotech Ltd.

List of Tables

  • Table 1 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By M-M-R II (2024-2032) ($MN)
  • Table 4 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By PRIORIX (2024-2032) ($MN)
  • Table 5 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Tresivac (2024-2032) ($MN)
  • Table 6 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By M-M-RvaxPro (2024-2032) ($MN)
  • Table 7 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 8 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Vaccine Type (2024-2032) ($MN)
  • Table 9 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Standalone Vaccines (2024-2032) ($MN)
  • Table 10 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Combination Vaccines (2024-2032) ($MN)
  • Table 11 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Route of Administration

Table (2024-2032) ($MN)

  • Table 12 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Subcutaneous Injections (2024-2032) ($MN)
  • Table 13 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Intramuscular Injections (2024-2032) ($MN)
  • Table 14 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Age Group (2024-2032) ($MN)
  • Table 15 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Infants (0-1 year) (2024-2032) ($MN)
  • Table 16 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Children (1-12 years) (2024-2032) ($MN)
  • Table 17 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Adolescents (2024-2032) ($MN)
  • Table 18 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Adults (2024-2032) ($MN)
  • Table 19 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 20 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 21 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Government Suppliers (2024-2032) ($MN)
  • Table 22 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 23 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By NGO & International Aid Programs (2024-2032) ($MN)
  • Table 24 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By End User (2024-2032) ($MN)
  • Table 25 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 26 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Public Health Agencies (2024-2032) ($MN)
  • Table 27 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Pediatric Clinics (2024-2032) ($MN)
  • Table 28 Global Measles, Mumps, Rubella (MMR) Vaccines Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.